Form **8937**
(December 2017)
Department of the Treasury
Internal Revenue Service

Report of Organizational Actions Affecting Basis of Securities

▶ **See separate instructions.**

OMB No. 1545-0123

Part I Reporting Issuer

1 Issuer's name	2 Issuer's employer identification number (EIN)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED	98-0478099

3 Name of contact for additional information	4 Telephone No. of contact	5 Email address of contact
YARON KATZ	888-838-2872	YARON.KATZ@TEVAPHARM.COM

6 Number and street (or P.O. box if mail is not delivered to street address) of contact	7 City, town, or post office, state, and ZIP code of contact
400 Interpace Parkway, #3	Parsippany, New Jersey 07054, USA

8 Date of action	9 Classification and description
September 14, 2026	Teva ADSs and Teva Ordinary Shares

10 CUSIP number	11 Serial number(s)	12 Ticker symbol	13 Account number(s)
881624209 & M8769Q102	N/A	TEVA	N/A

Part II Organizational Action Attach additional statements if needed. See back of form for additional questions.

14 Describe the organizational action and, if applicable, the date of the action or the date against which shareholders' ownership is measured for the action ▶ See attached.

15 Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per share or as a percentage of old basis ▶ See attached.

16 Describe the calculation of the change in basis and the data that supports the calculation, such as the market values of securities and the valuation dates ▶ See attached.

Part II Organizational Action *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ See attached.

18 Can any resulting loss be recognized? ▶ See attached.

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ See attached.

Sign Here

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Signature ▶ Date ▶ 10/07/2026

Print your name ▶ Yaron Katz Title ▶

Paid Preparer Use Only

Print/Type preparer's name	Preparer's signature	Date	Check ☐ if self-employed	PTIN
Firm's name ▶			Firm's EIN ▶	
Firm's address ▶			Phone no.	

Send Form 8937 (including accompanying statements) to: Department of the Treasury, Internal Revenue Service, Ogden, UT 84201-0054

TEVA PHARMACEUTICAL INDUSTRIES LIMITED
EIN: 98-0478099
Attachment to Form 8937 – Part II
Report of Organizational Actions Affecting Basis of Securities

---

The information contained herein is being provided pursuant to the requirements of Section 6045B of the Internal Revenue Code of 1986, as amended (the "Code"),[1] and includes a general summary regarding the application of certain United States ("U.S.") federal income tax laws and regulations related to the effects of the Conversion (as defined below) on certain securities held by U.S. taxpayers. The information contained herein does not constitute tax advice and does not purport to be complete or describe the tax consequences that may apply to particular persons or categories of persons. You should consult your own tax advisor regarding the particular consequences of the Conversion to you, including the applicability and effect of all U.S. federal, state, local and foreign tax laws.

Line 14 – Describe the organizational action and, if applicable, the date of the action or the date against which shareholders' ownership is measured for the action.

On September 14, 2026, TEVA PHARMACEUTICAL INDUSTRIES LIMITED (the "**Company**") terminated its American depositary share ("**ADS**") program, and each ADS was exchanged for one ordinary share of the Company (the **"Conversion"**). In connection with the Conversion, the Company's ordinary shares began trading on the New York Stock Exchange (the "**NYSE**") in place of the ADSs under the same ticker symbol, "TEVA." The Company's ordinary shares also continue to trade on the Tel Aviv Stock Exchange (the "**TASE**") under the ticker symbol "TEVA." Additional information is available in the investor relations section of the Company's website at ir.tevapharm.com.

The Company's ordinary shares listed on the TASE and on the NYSE constitute a single, fully fungible class of shares. Accordingly, beginning on September 14, 2026, shareholders may transfer their ordinary shares between the Israeli market (where the Tel Aviv Stock Exchange Clearing House provides central securities depository services) and the U.S. market (where the Depository Trust Company serves as the primary central securities depository for the ordinary shares).

Line 15 – Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per share or as a percentage of old basis.

The Conversion may have been a non-event for U.S. federal income tax purposes, may have constituted a "reorganization" within the meaning of Section 368(a)(1)(E) (a "**Recapitalization**"), or may have resulted in an exchange described in Section 1036 (a "**Section 1036 Exchange**"). In

[1] Unless otherwise specified herein, all "Section" references are to the Code.

either case, a shareholder's tax basis in a Company ordinary share it received in exchange for an ADS pursuant to the Conversion is the same as such shareholder's tax basis in such ADS.

For additional clarity, this mandatory exchange of Teva's ADRs into Teva ordinary shares should not be a taxable exchange for U.S. Federal income tax purposes, and a shareholder's tax basis in Teva ADRs should carry forward to the Teva ordinary shares.

The Company further notes that it does not believe it met the definition of a passive foreign investment company ("**PFIC**") for the tax year ending December 31, 2025, and accordingly, as of the date hereof (September 14, 2026), the Company does not believe that Section 1297, then Sections 1291 through 1298 are applicable.

Line 16 – Describe the calculation of the change in basis and the data that supports the calculation, such as the market values of securities and the valuation dates.

Each shareholder's aggregate tax basis in the Company's ordinary shares it received in exchange for ADSs pursuant to the Conversion remained the same immediately after the Conversion as such shareholder's aggregate basis in such ADSs immediately before the Conversion.

If an ADS holder held different blocks of ADSs (*i.e.*, ADSs acquired at different times or at different prices) at the time of the Conversion, such holder should consult its own tax advisor with respect to the determination of the tax basis in each ordinary share received in the Conversion.

Line 17 – List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based.

Section 354, Section 358, Section 368(a), and Section 1036.

Line 18 – Can any resulting loss be recognized?

No loss should be recognized by a shareholder as a result of the Conversion.

Line 19 – Provide any other information necessary to implement the adjustment, such as the reportable tax year.

The Conversion was effective September 14, 2026. For a shareholder whose taxable year is the calendar year, the reportable tax year is 2026, provided the Conversion constituted a Recapitalization or resulted in a Section 1036 Exchange.

* * * * *